邁博藥業-B(02181.HK)向科興生物製藥(688136.SH)授出CMAB008類停於內地獨家推廣許可
邁博藥業-B(02181.HK)公布,附屬「泰州藥業」與「科興生物製藥」(688136.SH)訂立獨家推廣服務協議,據此泰州藥業已向科興生物製藥授出CMAB008類停於內地(不包括香港、澳門及台灣)的獨家推廣許可。
CMAB008類停(英夫利西單抗)於去年7月獲國家藥品監督管理局批准上市,可用於治療成人潰瘍性結腸炎、強直性脊柱炎、類風濕關節炎、成人及6歲以上兒童克羅恩病、瘺管性克羅恩病、銀屑病。
泰州藥業將就此獨家推廣許可收取合作里程碑款及商業里程碑款項,雙方在該協議中約定了目標銷售量,如藥品銷售量未達目標,則泰州藥業有權解除合同或者由科興生物制藥根據該協議約定補償後繼續履行合同。而泰州藥業將繼續擁有CMAB008類停於內地,除推廣權外的所有權利及權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.